KAI Pharmaceuticals is Biotechnology in United States that focus on ocular angiogenesis business. Founded in 2002. They cover business area such as developer, biopharmaceutical drug, enzyme, cardiovascular and ischemic disease, pain, cancer, diabetes, inflammation, ocular angiogenesis, its pharmaceutical agent, secondary hyperparathyroidism.
2002
( 22 years old in 2024 )
Ocular Angiogenesis
-
270 Littlefield Avenue
South San Francisco, CA 94080
United States
Private
developerbiopharmaceutical drugenzymecardiovascular and ischemic diseasepaincancerdiabetesinflammationocular angiogenesisits pharmaceutical agentsecondary hyperparathyroidism
* We use standard office opening hours in near KAI Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
KAI Pharmaceuticals is Biotechnology business from United States that founded in 2002 (22 years old in 2024), KAI Pharmaceuticals business is focusing on Ocular Angiogenesis.
KAI Pharmaceuticals headquarter office and corporate office address is located in 270 Littlefield Avenue South San Francisco, CA 94080 United States.
KAI Pharmaceuticals was founded in United States.
In 2024, KAI Pharmaceuticals is currently focus on ocular angiogenesis sector.
Above is snippet of Google Trends for "ocular angiogenesis" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with KAI Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
